JP2016523925A5 - - Google Patents

Download PDF

Info

Publication number
JP2016523925A5
JP2016523925A5 JP2016524326A JP2016524326A JP2016523925A5 JP 2016523925 A5 JP2016523925 A5 JP 2016523925A5 JP 2016524326 A JP2016524326 A JP 2016524326A JP 2016524326 A JP2016524326 A JP 2016524326A JP 2016523925 A5 JP2016523925 A5 JP 2016523925A5
Authority
JP
Japan
Prior art keywords
amino
carbonyl
methylsulfamate
pyrimidin
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016524326A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016523925A (ja
JP6378759B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/045129 external-priority patent/WO2015002994A2/en
Publication of JP2016523925A publication Critical patent/JP2016523925A/ja
Publication of JP2016523925A5 publication Critical patent/JP2016523925A5/ja
Application granted granted Critical
Publication of JP6378759B2 publication Critical patent/JP6378759B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016524326A 2013-07-02 2014-07-01 Sumo活性化酵素阻害剤として有用なヘテロアリール化合物 Expired - Fee Related JP6378759B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361842097P 2013-07-02 2013-07-02
US61/842,097 2013-07-02
PCT/US2014/045129 WO2015002994A2 (en) 2013-07-02 2014-07-01 Heteroaryl compounds useful as inhibitors of sumo activating enzyme

Publications (3)

Publication Number Publication Date
JP2016523925A JP2016523925A (ja) 2016-08-12
JP2016523925A5 true JP2016523925A5 (enExample) 2017-08-10
JP6378759B2 JP6378759B2 (ja) 2018-08-22

Family

ID=52144279

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016524326A Expired - Fee Related JP6378759B2 (ja) 2013-07-02 2014-07-01 Sumo活性化酵素阻害剤として有用なヘテロアリール化合物

Country Status (8)

Country Link
US (1) US9695154B2 (enExample)
EP (1) EP3016934B1 (enExample)
JP (1) JP6378759B2 (enExample)
CN (1) CN105492429A (enExample)
BR (1) BR112015032902A8 (enExample)
CA (1) CA2916468C (enExample)
EA (1) EA032577B1 (enExample)
WO (1) WO2015002994A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
EP3173413B1 (en) 2012-02-17 2019-05-01 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
WO2014022744A1 (en) 2012-08-03 2014-02-06 Millennium Pharmaceuticals, Inc. INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF Uba6
BR112015032902A8 (pt) 2013-07-02 2019-12-24 Millennium Pharm Inc compostos de heteroarila, seus usos e composições farmacêuticas
EP3901159A1 (en) * 2014-07-01 2021-10-27 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme
KR101927375B1 (ko) 2016-04-20 2018-12-11 한국화학연구원 신규한 헤테로고리 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CN105670066A (zh) * 2016-04-22 2016-06-15 宁波硫华聚合物有限公司 橡胶促进剂活性剂氧化镁母胶粒及其制备方法
CN107586315B (zh) * 2016-07-08 2020-03-31 成都海创药业有限公司 一种嵌合分子
US10875834B2 (en) 2016-07-22 2020-12-29 Virginia Commonwealth University Prodrug and protected forms of 5-hydroxymethylfurfuranal (5-HMF) and its derivatives
JP7352582B2 (ja) 2018-07-09 2023-09-28 武田薬品工業株式会社 Sumo活性化酵素阻害剤及び抗cd20抗体の投与
WO2020023846A1 (en) * 2018-07-27 2020-01-30 Arcus Biosciences, Inc. Pyridone a2r antagonists
US11578079B2 (en) 2018-07-31 2023-02-14 City Of Hope SUMO inhibitor compounds and uses thereof
EP3930719B1 (en) 2019-02-27 2025-08-20 Takeda Pharmaceutical Company Limited Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
WO2022159980A1 (en) * 2021-01-25 2022-07-28 Athos Therapeutics, Inc. Pharmaceutical compounds and methods of making and using the same
WO2023073645A1 (en) 2021-10-29 2023-05-04 Takeda Pharmaceutical Company Limited Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
JP2025534374A (ja) * 2022-09-30 2025-10-15 ウィゲン・バイオメディシン・テクノロジー・(シャンハイ)・カンパニー・リミテッド Sumo活性化酵素阻害剤としての化合物
WO2024097736A1 (en) * 2022-11-02 2024-05-10 Arcus Biosciences, Inc. Processes for preparing azolopyrimidine compounds
WO2024099438A1 (zh) * 2022-11-11 2024-05-16 微境生物医药科技(上海)有限公司 作为sumo活化酶抑制剂的化合物
CN116640068A (zh) * 2023-05-26 2023-08-25 康化(上海)新药研发有限公司 一种(3-环丙基-2-炔-1-基)甘氨酸苄酯的合成方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194446A (en) 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
AU6500696A (en) 1995-07-28 1997-02-26 Cubist Pharmaceuticals, Inc. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents
US20040023901A1 (en) 2002-02-28 2004-02-05 Cook Phillip D. Nucleoside 5'-monophosphate mimics and their prodrugs
US7291603B2 (en) 2002-07-24 2007-11-06 Ptc Therapeutics, Inc. Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
CA2493816A1 (en) 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
CN1701073B (zh) 2002-09-04 2011-06-22 先灵公司 作为细胞周期蛋白依赖激酶抑制剂的吡唑并[1,5-a]嘧啶
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
WO2004022559A1 (en) 2002-09-04 2004-03-18 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004043955A1 (en) 2002-11-13 2004-05-27 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
EP1608652A1 (en) 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ[1,5−a]ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
US20050130974A1 (en) 2003-10-17 2005-06-16 Rigel Pharmaceuticals, Inc. Benzothiazole compositions and their use as ubiquitin ligase inhibitors
JPWO2005051949A1 (ja) 2003-11-26 2007-06-21 住友製薬株式会社 新規縮合イミダゾール誘導体
JP2008503591A (ja) 2004-06-22 2008-02-07 ライジェル ファーマシューティカルズ, インコーポレイテッド ユビキチンリガーゼ阻害剤
AU2006210422B2 (en) 2005-02-04 2012-09-13 Takeda Pharmaceutical Company Limited Inhibitors of E1 activating enzymes
WO2007044426A2 (en) 2005-10-06 2007-04-19 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
CN106008512B (zh) * 2006-02-02 2019-03-12 千禧药品公司 E1活化酶抑制剂
HRP20110017T1 (hr) * 2006-08-08 2011-02-28 Millennium Pharmaceuticals Spojevi heteroarila korisni kao inhibitori e1 aktivirajućih enzima
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
JP5539864B2 (ja) 2007-06-12 2014-07-02 アカオゲン,インコーポレーテッド 抗菌剤
WO2009082691A1 (en) 2007-12-21 2009-07-02 Board Of Regents, University Of Texas System Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
US8470834B2 (en) 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AU2009282571B2 (en) 2008-08-20 2014-12-11 Merck Sharp & Dohme Corp. Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734486A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TW201020238A (en) 2008-08-20 2010-06-01 Schering Corp Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP3587434A1 (en) 2008-09-23 2020-01-01 Alnylam Pharmaceuticals Inc. Chemical modifications of monomers and oligonucleotides with click components for conjugation with ligands
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
SG10201402148SA (en) 2009-05-14 2014-07-30 Millennium Pharm Inc Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
CA2771190C (en) 2009-08-17 2020-01-21 Memorial Sloan-Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
WO2011100131A2 (en) 2010-01-28 2011-08-18 Alnylam Pharmacuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
EP2536410B1 (en) 2010-02-18 2015-09-23 Merck Sharp & Dohme Corp. Substituted pyrimidine derivatives and their use in treating viral infections
EP3064204A1 (en) 2010-03-01 2016-09-07 GTx, Inc. Compounds for treatment of cancer
CA2806341C (en) 2010-07-29 2020-03-24 Rigel Pharmaceuticals, Inc. Ampk-activating heterocyclic compounds and methods for using the same
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
MX2014002015A (es) * 2011-08-24 2014-03-27 Millennium Pharm Inc Inhibidores de la enzima activadora de nedd8.
EP2764121A4 (en) * 2011-10-07 2015-09-02 Millennium Pharm Inc E1-ENZYM MUTANTS AND USES THEREOF
WO2013066729A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
EP3173413B1 (en) 2012-02-17 2019-05-01 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
BR112015032902A8 (pt) 2013-07-02 2019-12-24 Millennium Pharm Inc compostos de heteroarila, seus usos e composições farmacêuticas
WO2015048547A2 (en) 2013-09-26 2015-04-02 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
RU2019131017A (ru) 2013-10-21 2019-11-25 Мерк Патент Гмбх Соединения гетероарила в качестве ингибиторов btk и их применение
WO2015110999A1 (en) 2014-01-24 2015-07-30 Piramal Enterprises Limited Ezh2 inhibitors and uses thereof

Similar Documents

Publication Publication Date Title
JP2016523925A5 (enExample)
JP2016523911A5 (enExample)
TWI327137B (enExample)
RU2015143517A (ru) Пиразолсодержащие соединения и их применения
JP6378759B2 (ja) Sumo活性化酵素阻害剤として有用なヘテロアリール化合物
TWI377910B (en) Hydrazide compound and pesticidal use of the same
HRP20230244T1 (hr) Derivati 3-(1-oksoizoindolin-2-il)piperidin-2,6-diona i njihova upotreba
JP2017502049A5 (enExample)
RU2021133444A (ru) Производные бензимидазола в качестве модуляторов ror-гамма
JP2010533158A5 (enExample)
JP2018520170A5 (enExample)
JP2011503166A5 (enExample)
CA2351725A1 (en) Substituted pyrazoles as p38 kinase inhibitors
RU2014110172A (ru) Гетероциклическое производное и фармацевтическое средство
HRP20230789T1 (hr) Derivati benzhidroksamske kiseline kao selektivni inhibitori hdac6
JP2006503057A5 (enExample)
JP2015500332A5 (enExample)
JP2019516737A5 (enExample)
RU2016102137A (ru) Первичные карбоксамиды в качестве ингибиторов bik
JP2013533868A5 (enExample)
JP2018530591A5 (enExample)
CA2670605A1 (en) Substituted arylpyrazoles
JP2011513221A5 (enExample)
RU2019113764A (ru) Соединения хиноксалина в качестве ингибиторов рецепторной тирозинкиназы iii типа
JP2008526840A5 (enExample)